Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

细胞因子释放综合征 医学 外周血单个核细胞 多发性骨髓瘤 免疫系统 免疫学 T细胞 醛类白血病 流式细胞术 内科学 肿瘤科 药理学 生物 嵌合抗原受体 体外 生物化学
作者
Yongxian Hu,Yanlei Zhang,Guoqing Wei,Chang alex Hong,He Huang
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 1859-1859 被引量:9
标识
DOI:10.1182/blood-2019-130341
摘要

Background BCMA CAR-T cells have demonstrated substantial clinical activity against relapsed/refractory multiple myeloma (RRMM). In different clinical trials, the overall response rate (ORR) varied from 50% to 100%. Complete remission (CR) rate varied from 20% to 80%. Here we developed a BCMA CAR-T cell product manufactured via lentiviral vector-mediated transduction of activated T cells to express a second-generation CAR with 4-1BB costimulatory domain and evaluated the efficacy and safety, moreover, dynamics of immune cell subsets using single-cell mass cytometry during treatment were analyzed. Methods Our trial (ChiCTR1800017404) is a phase 1, single-arm, open-label single center study to evaluate the safety and efficacy of autologous BCMA CAR-T treatment for RRMM. Patients were subjected to a lymphodepleting regimen with Flu and Cy prior to CAR-T infusion. BCMA CAR-T cells were administered as a single infusion at a median dose of 3.5 (1 to 6) ×106/kg. MM response assessment was conducted according to the International Uniform Response Criteria. Cytokine-release syndrome (CRS) was graded as Lee DW et al described (Blood.2014;124(2):188-195). Phenotypic analysis of peripheral blood mononuclear cells (PBMCs), frozen BCMA CAR-T aliquots, phenotype and in vivo kinetics of immune cell subsets after CAR-T infusion were performed by single-cell mass cytometry. Results As of the data cut-off date (August 1st, 2019), 33 patients, median age 62.5 (49 to 75) years old were infused with BCMA CAR-T cells. The median observation period is 8.0 (0.7 to 18) months. ORR was 100% (The patient who died of infection at 20 days after CAR-T infusion were excluded). All the 32 patients achieved MRD negative in bone marrow by flow cytometry in 2 weeks after CAR-T infusion. Partial response (4 PR, 12.1%), VGPR (7 VGPR, 21.2%), and complete response (21 CR, 63.6%) within 12 weeks post CAR-T infusion were achieved. Durable responses from 4 weeks towards the data cut-off date were found in 28/33 patients (84.8%) (Figure 1a). All patients had detectable CAR-T expansion by flow cytometry from Day 3 post CAR-T cell infusion. The peak CAR-T cell expansion in CD3+ lymphocytes of peripheral blood (PB) varied from 35% to 95% with a median percentage of 82.9%. CRS was reported in all the 33 patients, including 4 with Grade 1, 13 with Grade 2 and 16 with Grade 3. During follow-up, 1-year progression-free survival (PFS) was 70.7% (Figure 1b) and overall survival (OS) was 71.7% (Figure 1c). Multivariate analysis of patients with PR and patients with CR+VGPR revealed that factors including extramedullary infiltration, age>60 years old, high-risk cytogenetics, late stage and CAR-T cell dose were not associated with clinical response (P>0.05). Single-cell mass cytometry revealed that the frequency of total T cells, CD8+ T cells, NK cells and CD3+CD56+ NKT cells in PB was not associated with BCM CAR-T expansion or clinical response. CD8+ Granzyme B+ Ki-67+ CAR-T cells expanded prominently in CRS period. As serum cytokines increased during CRS, non-CAR-T immune cell subsets including PD1+ NK cells, CD8+ Ki-67+ ICOS+ T cells expanded dominantly implying that non-CAR-T cells were also activated after CAR-T treatment. After CRS, stem cell like memory CAR-T cells (CD45RO+ CCR7- CD28- CD95+) remain the main subtype of CAR-T cells (Figure 1d). Conclusions Our data showed BCMA CAR-T treatment is safe with prominent efficacy which can overcome the traditional high-risk factors. We also observed high expansion level and long-term persistence of BCMA CAR-T cells contribute to potent anti-myeloma activity. Stem cell like memory CAR-T cells might be associated with long-term persistence of BCMA CAR-T cells. These initial data provide strong evidence to support the further development of this anti-myeloma cellular immunotherapy. Figure 1. Disclosures No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
执着的冬瓜完成签到 ,获得积分10
2秒前
酷波er应助无奈盼波采纳,获得10
4秒前
wade发布了新的文献求助10
4秒前
linyu发布了新的文献求助10
4秒前
5秒前
pjh完成签到,获得积分10
5秒前
斯文败类应助dad采纳,获得10
6秒前
mizhou发布了新的文献求助10
7秒前
7秒前
坩埚钳完成签到,获得积分10
10秒前
久而久之发布了新的文献求助10
13秒前
充电宝应助大狒狒采纳,获得10
13秒前
14秒前
无奈盼波完成签到,获得积分20
14秒前
隐形曼青应助长情尔曼采纳,获得10
15秒前
15秒前
SucceedIn完成签到,获得积分10
16秒前
Wtony完成签到 ,获得积分10
17秒前
18秒前
无奈盼波发布了新的文献求助10
19秒前
超人Steiner完成签到 ,获得积分10
19秒前
19秒前
小宝爸爸发布了新的文献求助10
19秒前
20秒前
酷波er应助myy采纳,获得10
20秒前
傻傻的凤灵应助清秀代天采纳,获得10
20秒前
发一篇Nature完成签到 ,获得积分10
22秒前
我不爱池鱼完成签到,获得积分0
22秒前
chrysophoron完成签到,获得积分10
22秒前
23秒前
科研通AI2S应助。。。采纳,获得10
23秒前
23秒前
元元元yuan完成签到,获得积分10
24秒前
sara发布了新的文献求助10
24秒前
24秒前
lj完成签到,获得积分10
28秒前
猪猪hero应助无奈盼波采纳,获得10
28秒前
29秒前
wanci应助Chelry采纳,获得10
30秒前
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
Current Perspectives on Generative SLA - Processing, Influence, and Interfaces 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3991847
求助须知:如何正确求助?哪些是违规求助? 3532997
关于积分的说明 11260291
捐赠科研通 3272252
什么是DOI,文献DOI怎么找? 1805688
邀请新用户注册赠送积分活动 882609
科研通“疑难数据库(出版商)”最低求助积分说明 809425